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license (http://creativecommons.org/Summary Biomedical materials have been developed for facilitating tissue regeneration and
healing enhancement. Although research on biomedical materials has made great progress in
material innovation and preclinical testing, the bottleneck is their translation from research
and development to clinical applications; that is, the current rate of product registration
and industrialization is low, which directly affects their clinical applications. In this paper,
we introduce the basic features of biomedical materials towards the making of medical prod-
ucts and the experiences of our group in research and clinical translation of biomaterials for
bone-tissue regeneration in the last few years. Based on our experience, we propose that
the translational medicine platform (TMP) is an effective route to facilitate the progress of
biomedical materials from bench to bedside. Moreover, from the viewpoints of scientific tech-
nology and management, the functions of TMP were also addressed. Relationships among TMP,
research institution, enterprise, and government were also explored from the viewpoints of
technological innovation, chemical engineering integration, fund raising, and management.
This paper provides a theoretical and practical reference for clinical translation of biomedical
materials.
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Biomedical materials are a group of special functional
materials that aid in the diagnosis, treatment, recovery or
replacement of diseased or damaged tissues or organs, and
promoting functions of physiological systems. The use of
medical materials not only saves the lives of many patients
and significantly decreases the death rate of patients with
various medical conditions, such as wounds and cancers,
but also plays an important role in improving the quality of
life and health of patients. Health issues have become a
great challenge worldwide. Because of the more frequent
occurrence of diseases, natural disasters, traffic accidents,
and population ageing, the requirement for biomedical
materials in clinical applications is rapidly growing, and
biomedical instruments are predicted as a new growth
point in the world economy [1,2].
There are 60 million physically challenged people out of
the 1.3 billion people living in China. According to available
statistical data, there are 70 million patients with osteo-
porosis, more than 0.3 billion people with various dental
problems, 0.15 million patients undergoing joint replace-
ment surgery annually, millions of people undertaking
cosmetic surgery, and more than 20 million with coronary
heart disease or cardiovascular disease. Therefore, the
demand for biomedical materials is very high, which is ex-
pected to increase with the further development of rural
markets [2,3]. Unfortunately, in China, less than 5% of
biomaterials and medical instruments are manufactured
domestically. In addition, the availability of products
required for making these biomaterials is often limited and
some products may result in less satisfactory treatment
outcome. Meanwhile, huge financial profits and market
potential have greatly attracted overseas’ companies into
domestic markets, and thus the percentage of high-level
products supplied by domestic enterprises are signifi-
cantly reduced. Consequently, domestic enterprises are
experiencing great frustration and the cost for medical
treatment is subsequently increasing. To solve these prob-
lems completely, independent research and development
(R&D) of high-performance biomedical materials is urgently
needed.R&D of biomedical materials towards clinical
translations
Translational medicine in orthopaedics has become a focus
of local and international medical communities, especially
in the development of biomedical materials [4e6].
Biomedical materials have been developed in China for
more than 20 years. However, both fundamental research
and technological development are far behind that of the
developed countries. In the past few years, under the
support of National Natural Science Foundation of China,
National Basic Research Programme of China (973 Pro-
gramme), and National High Technology Research and
Development Programme (863 Programme), the research of
biomedical materials in China has made great progress from
low-level repetition to programme-oriented and cutting-
edge development in some aspects of this discipline.For many years, the biomaterials research group of the
East China University of Science and Technology (ECUST)
has focused on the clinical demand-driven development
and R&D of bone-tissue-repair materials. We also have
tried our best to promote our research outcomes towards
industrializations and clinical applications. For example,
based on the biology of wound healing and the self-
repairing potential of the human body, we have proposed
and developed a bioreactor that possesses the function
of in situ-guided tissue regeneration by synergistic ef-
fects of biomaterials and growth factors. In this reactor,
tissue cells can adhere, grow, and differentiate on the
scaffold surface, thereby promoting new bone formation
accompanied by the degradation of the scaffold materials
[7,8].
Our group is the first to study calcium phosphate cement
(CPC) in China [9e11]. Based on the theories and method-
ologies in chemical engineering, the transformation mech-
anisms of specific kinds of ultrafine calcium phosphates in
liquidesolid systems were thoroughly investigated. We
successfully prepared CPC with high purity and high activity
by a series of processes, including micromixing, heteroge-
neous nucleation, heat treatment, pore formation at room
temperature, and control of the degradation rate to meet
biological and physiological needs in bone-defect repair. In
addition, our group systematically investigated the hy-
drating and hardening mechanisms of CPC. Based on these
basic studies, osseointegration characteristics and degra-
dation mechanisms of the prepared CPC were confirmed by
in vivo animal experiments. With the superior properties of
self-setting, easily shaped capability, biocompatibility, and
biodegradability, we have successfully obtained the first
product registration for CPC materials certified by the State
Food and Drug Administration (SFDA). Our CPC has been
applied in more than 500 hospitals and in over 240,000
patients in big cities such as Beijing and Shanghai.
Furthermore, a series of CPC-based bone-tissue-repair
materials, including drug-loaded CPC, injectable CPC, and
porous CPC, has been developed (Fig. 1).
To further improve the therapeutic efficacy, especially
for patients with large or critical bone defects and for
elderly patients with poor bone-regeneration potential,
recombinant human bone morphogenetic protein-2 (rhBMP-
2)-loaded bone-tissue scaffold has been developed [12,13].
Using genetic engineering technology, rhBMP-2 with high
purity and high bioactivity has been successfully prepared
by optimization of Escherichia coli expression system,
construction of engineering bacteria, and expression and
purifying technologies and has been patented in the United
States [12]. In addition, the scale up (30 mg/batch) of
rhBMP-2 was achieved as well. Based on these results, we
have systematically studied the effects of the chemical
composition, surface/interface structure of the materials,
and other small molecular medicines on microstructure,
presentation, and bioactivity of rhBMP-2. Based on these
fundamental studies, we have fabricated rhBMP-2/CPC
scaffold with enhanced osteogeneration potential [13]. Up
to now, we have applied this new rhBMP-2/CPC scaffold for
68 patients with limb fractures and vertebral fusion. Our
CPC has shown great clinical efficacy in enhancing bone
regeneration. The rhBMP-2/CPC has also been authorized
by the SFDA [armed (2013) No. 3460199].
Figure 1 Series of calcium phosphate cement-based products developed for bone-tissue regeneration approved for clinical
applications in China.
Clinical translation of biomedical materials and product registration 51After over 10 years, we have indeed realized that the
road from R&D to clinical translation needs multidisci-
plinary teams to work together for many years and the
barriers for successful clinical translation are the product
development and registration.Consideration of the clinical translation of
biomedical materials
The clinical translation of biomedical materials can not only
effectively relieve the patients’ pain and improve patients’
life quality, but it can also contribute to remarkable so-
cioeconomic profits. By contrast, the financial profits
gained from clinical applications and the experience from
clinical practice can further promote the fundamental
research of biomedical materials and their R&D through
virtuous cycle between basic research and clinical appli-
cations. However, this is a very complicated process and
requires efforts from many participating institutions, in-
dustries, and regulatory bodies. Based on the experience in
promoting industrialization of self-setting CPC by the
ECUST, we will discuss the difficulties, experiences, and
lessons in the clinical transformation process of biomedical
materials [14].
Characteristics of the biomedical materials and
their main obstacles in the process of
transformation from bench to bedside
Biomedical materials application is a relatively new branch
of science with a multidisciplinary nature involving biology,
materials, chemistry, and medicine. The commercialization
of biomedical materials often includes laboratory research,
pilot experiments, clinical trials, drug-approval pro-
gramme, product registration, and marketing or clinical
applications. Thus, the transformation of biomedical ma-
terials to clinical applications requires a tight cooperation
among government, research institutions, companies, and
hospitals.
However, there are some critical issues that need to be
addressed before transforming biomedical materials to
clinical applications. First, research institutions, hospitals,and enterprises are independent of each other. The
connection between basic research and clinical application
is still poor, and thus the technology developed in a
research laboratory cannot meet the demands of clinical
needs. Second, chemical engineering is comparatively weak
and effective engineering integration is desirable. Third,
the absence of platform organizations with strong research
capacity, familiar with relative law and regulatory re-
quirements and market operation at the same time, results
in the disconnection of research and application. Fourth,
although the translation from research to clinical applica-
tion is a long-term task, long-term strategic support for
funds from government or enterprises with long-term
development visions is often limited, which is in fact rare
in developed countries. All these are critical obstacles in
the effective translation from fundamental research to
clinical application, and thus the rate of clinical translation
of biomedical materials is very low. Low clinical translation
rate and the long duration involved in obtaining product
registration are the major obstacles, and these create a
huge gap between research investment and the health
demand in China. Therefore, great attention must be paid
to find a solution to shorten the period of translation of
fundamental research to clinical application, thereby
accelerating the clinical translation in the field of
biomedical materials.Translational medicine platform
A good approach to bridge the gap from basic research to
clinical application is to establish a translational medicine
platform (TMP). The core of the TMP is to establish effec-
tive ties among basic medical researchers, public health
workers, and doctors, particularly to translate the
biomedical research results to suitable disease prevention,
diagnosis, treatment, and prevention methods effectively.
Therefore, the mission or objective of TMP, from a tech-
nical viewpoint, is to build a bridge between research in-
stitutions and enterprises. Efficient translation and
application centres or laboratories should be established,
which mainly takes care of the technology development in
the process of medical translation and facilitates the con-
version of product R&D to clinical application [15,16]. The
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52 Y. Yuan et al.detailed process is summarized in Fig. 2. By contrast, from
a management’s viewpoint, an administration department
should be established, including commission of experts,
management office, and outreach coordination office,
which mainly coordinate the relationships among hospitals,
research institutions, and enterprises to create a novel
market-oriented technological innovation, strengthen the
integration process and the connection between scientific
technology and management. This will facilitate the for-
mation of an advanced and highly efficient management
model.Enterprise
Figure 3 Illustration of innovation of technology.
R&D Z research and development.TMP-based clinical translation for biomedical
materials
The TMP-based clinical translation process for biomaterials
will be discussed regarding the following points:
 Focussing on clinical application and launching market-
oriented technological innovation
The source of biomaterial innovation is from the clinical
needs-based market information and feedback from exist-
ing clinically approved biomaterials. Only by close follow-
up of the market situations and good understanding of the
market demand, together with a series of outbreaks in key
technology or other related fields, the products designed
can meet the requirement of clinical applications and
market needs. This is essential to provide sustainable
development of enterprises and may subsequently help the
enterprises to expand and get into a revenue-generation
cycle. Therefore, from this viewpoint, R&D of biomedical
materials must be geared towards the demands of the
market and strengthen the basic application research.
Generally speaking, science and technology innovation
needs both knowledge innovation and technology innova-
tion, and technology innovation often comes from our
knowledge innovation (Fig. 3). During this process, aca-
demic and research institutions are the core of funda-
mental research and knowledge innovation, and enterprises
are the centre of technology innovation. Subsequently,
science and technology innovation needs close cooperation
and joint efforts from research institutions and enterprises.
Here, we will demonstrate a successful collaborative
innovation between research institutions and enterprisesPilot Technology
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Figure 2 Distribution of responsibility within the trans-
lational medicine platform.using an example of a technological innovation in osteoin-
ductive bone-repair materials developed in the ECUST.
With the clinical demands on highly bioactive bone-repair
materials, our group has carried out basic research and
knowledge innovation from the controllable preparation of
the composite materials, maintenance of bioactivity with
sustainable release of incorporated growth factors, syner-
gistic action of small molecules, and immobilization of
growth factors onto the designed biomaterial matrix.
Meanwhile, Shanghai Rebone Biomaterials Co. Ltd., which
has been formed as a spin-off company of the ECUST and
shares the R&D and translational duties with the ECUST,
mainly focuses on the industrialization, scale up of the
matrix preparation and growth factors, and so on (Fig. 4).
 Emphasizing engineering and technology integration
and improving the comprehensive properties of
biomedical materials
The first step in engineering research of the biomedical
materials is scale up of the synthesis of biomaterials. Usually,
the fabrication of biomedical materials mainly includes
material preparation and activation, such as assembly of
growth factors, which is very different from traditional
translational engineering. The purpose of the regulation and
optimization of biological materials is to improve the bio-
logical performances and safety of the materials, and not
just the conversion rate and selectivity in traditional chem-
ical engineering. The regulation of the materials’ perfor-
mances and engineering factors often interact with each
other, which makes the R&D become more and more
complicated. The conventional chemical process of a prod-
uct mainly contains three elements, namely, materials,
processing rate, and product conditions. The product per-
formance is mainly modulated by chemical composition and
the key to the scale up is selectivity and yield during the
process. However, the development and active assembly of
biomedical materials often involve five elements, namely,
materials, microstructure, biological activity, processing
rate, and product conditions. The final application perfor-
mance not only depends on its chemical composition, but
also relies on its microstructure and biological activity.
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Figure 4 Collaboration between the R&D unit and spin-off
company in technological innovation of osteoinductive bone-
repair materials. ECUST Z East China University of Science
and Technology; R&D Z research and development.
Clinical translation of biomedical materials and product registration 53Therefore, the final purpose of the preparation process is
chemical composition, bioactivity, and application perfor-
mance of the materials. The economic benefits of the pro-
cess depend on productivity and performance of the
products. Furthermore, the materials’ composition, three-
dimensional structure, interfacial surface, and bioactive
factor often have aneffect on blood coagulation, bioactivity,
and degradation in vivo. Therefore, it is very difficult to take
a single element into account to represent the entire pro-
cess. We must explore the effects of composition of mate-
rials, three-dimensional structure, surface status, and
bioactive factors together during the process of research,
which directly leads to a much more complicated process
involving preparation of materials, activity assembly, mixed
flowing, and transferring mass. Therefore, from this view-
point, it is necessary to combine traditional chemical engi-
neering with the features of biological materials. The
possibility of industrialization must be considered from the
selection of methods and raw materials.
Besides the scale up of biomedical materials, a suc-
cessful clinical translation must emphasize the safety and
operability of the biomaterials, and their clinical in-
dications. In addition, the related supporting equipment
must also be considered. Therefore, the entire process is
systematic engineering.
 Combining the technological and investment factors to
solve the funding shortage in the process of
industrialization
Because of the long periods involved in R&D and clinical
translation, as well as the high risk involved, government
and big enterprises or companies often invest very little in
the early stages. Therefore, insufficient funding is one of
the main factors restricting the successful translation of
biomedical materials into clinical applications.
From this point, the government should strengthen in-
vestment and take different measures depending on the
features during the various stage of the development. To
realize it, the government can deploy the following three
important programmes: cultivating innovative technology,
facilitating technology integration, and promoting indus-
trialization. The government also should develop various
preferential policies for importing advanced technologies
and try best to guide the investment effectively from all
aspects of the society. At the same time, governmentshould also pay attention to the long-term strategic in-
vestment to normalize risky investment system and pro-
mote efficient combination of technological elements and
financial investments.
The relevant enterprises should also initiate multi-
investment systems to raise funding and provide a founda-
tion on which to develop and grow the biomedical materials
field. Only by promoting a combination of technology and
funding factors, fluxion of funds and property rights, can the
intelligence, technology, cash, and management be effec-
tively integrated. As a result, the technology of the
biomedical materials can be brought out and the funding
obstacles during the industrialization process can be solved.
 Establishing an advanced management model in line
with the development of biomedical materials
Because the R&D of biomedical materials involves high
costs and long cycles in the translation process, it can be
easily impaired by external social and economic environ-
ments. Therefore, the related enterprise should fully un-
derstand the industrial internal and external conditions,
and carry out an advanced management model to achieve
effective organization and management. This is very
important to promote industrialization of biomedical
materials.
First, clinical translation of biomedical materials re-
quires great attention to the relative laws and ethical issues
during the whole process. The final application of the
biomedical materials is for the human body, and the eval-
uation of biomedical materials often includes safety,
therapeutic effect, and the medical ethical issue relative
laws and international practices. Therefore, the biomedical
enterprises should always pay attention to the biomedical
material-related constructional strategy carried out by the
government and try to avoid malpractice during the process
of industrialization.
Second, with regard to daily management, enterprises
should closely or intensely control the quality of products
and test the products carefully, ensure the safety of
products and undertake the responsibility and obligation
for the final quality of the products. In the meantime, the
company should also establish a novel management model
in line with the development of a high-tech enterprise. By
these strategies, the enterprise can ignite the passions of
talents and backbone and reduce the risk in the process of
clinical translation.
 Optimizing supervision of the government
By studying and referring the advanced management
experience of the developed countries, we should
strengthen the administrative supervision, improve the
level of management, and standardize the market order.
Considering the specific conditions in China, we should
build a unified, standardized, internationally monitored
evaluation system in the field of biomedical materials. For
example, various evaluation methods should be taken for
different products, and gradually improve the tightly and
one-side-oriented phenomenon. The 510K contents estab-
lished by the United States Food and Drug Administration is
an excellent example [17].
54 Y. Yuan et al.First, we should change the current situation, where
the registration review is strict and daily supervision is
relatively loose after the product has been certified. The
key problem is not certification, but close supervision in
the ensuing operation and daily management. Therefore,
we must combine the rigorous market certification with
strict supervision. Only by combination, the contradiction
between governmental effective supervision and enter-
prise development can be effectively resolved. In addi-
tion, the safety of the biomedical product can also be
ensured.
Second, we should change the attitudes towards the
domestic products. The domestic products are as important
as the products fabricated for export. For the indepen-
dently innovative domestic products, we should build a
priority-review and fast-review programme and break out
the boundary in product registration and approval. More-
over, by clearing the obstacles of circulation process of
biomedical materials and cleaning up the abnormal phe-
nomenon during the bidding process, a better market order
should be established.
Third, for promoting the development of the technology
and market in the field of biomedical materials, the gov-
ernment should build a domestic and international network
to recruit talent, technology, resources, and management.
By doing this, independent R&D centres, industry-specific
common technology, and top-level talent and resources can
be formed, which will subsequently result in the healthy
development of biomedical materials in China.
 Strengthening the role of the product registration
consultation company
The review and registration by SFDA is the most difficult
and tough step for the translation of research outcome to
clinical application. Different products have different
evaluation requirement and standards. Therefore, to speed
up the process, the TMP should establish a registration
consultation company, and the researcher and enterprise
should strengthen the communication with them. The
registration consultation company should provide the
guideline of all related policies and laws, offer assistances
in file preparation, safety evaluation, and so on. The
consultation company can also help the company to run
registration smoothly and obtain reliable results, and thus
the registration process efficiency of biomedical materials
will be improved. The most important objective of this
consultation company is to ensure that the research result
registration is easier and efficient.
In summary, China is experiencing a critical time in
building a well-off society and stepping into the developed
country. We should aim at the clinical demands of the
country and build up TMP, where our research institutions,
enterprises, and clinics shall collaborate efficiently and
play their own unique role in R&D and clinical translation of
biomedical materials. This collective effort will form sus-
tainable self-innovation ability for developing biomedical
materials and shorten the gap or time between R&D and
industrialization. By creating innovative and novel ideas,
new methods and a new strategic programme, we can make
R&D of clinically orientated biomedical materials become
one of the national’s high- and new technology industries.Conflicts of interest
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